CLEVELAND, July 16, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced the appointment of Dr. Gail Wilensky to its Board of Directors,
effective today.
Dr. Wilensky has an extensive track record in healthcare as a
policy leader, reimbursement expert, and board member. She is
currently a Senior Fellow at Project HOPE, an international
non-profit health foundation. She served in the White House as a
senior adviser on health and welfare issues to President
George H.W. Bush and directed the
Medicare and Medicaid programs. Gail was also the first chair of
the Medicare Payment Advisory Commission.
Dr. Wilensky serves as a director for Quest Diagnostics, United
Health Group, the Geisinger Health System Foundation, and is on the
Board of Regents of the Uniformed Services
University of the Health Sciences (USUHS). She is an elected
member of the National Academy of Medicine and has served two terms
on its governing council. Dr. Wilensky was a former chair of the
board of directors of Academy Health and a trustee of the American
Heart Association. She received a B.A., M.A., and a Ph.D. from the
University of Michigan and has received
several honorary degrees.
"ViewRay is a leading innovator with a promising opportunity to
become the standard of care in radiation oncology," stated Dr.
Wilensky. "I look forward to working with the team at this critical
time in the Company's evolution."
ViewRay also announced that Ted
Wang is retiring from its Board of Directors effective
July 15, 2019. "It has been a
privilege to serve on ViewRay's board and help the company
transition from an early-stage, innovative technology company to an
organization that is making a profound impact on the lives of
cancer patients around the world. ViewRay has a very exciting
future ahead," said Wang.
"On behalf of ViewRay, I wish to thank Ted for his many
contributions to the Board of Directors and his meaningful impact
on the company. We are also delighted to welcome Gail to the board.
She is an impressive leader with a deep understanding of
healthcare, and her career efforts have helped to improve the lives
of millions. She is an outstanding addition to our board," said
Dan Moore, Chairman of the Board of
ViewRay.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams. ViewRay and MRIdian are
registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2019 and ViewRay's conference call to discuss its first
quarter results. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to commercialize MRIdian
Linac System, demand for ViewRay's products, the ability to convert
backlog into revenue, and the timing of delivery of ViewRay's
products, the timing, results and other uncertainties associated
with clinical trials, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to ViewRay's
business in general, see ViewRay's current and future reports filed
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Report on
Form 10-Q for the fiscal quarter ended March
31, 2019, as updated periodically by the company's other
filings with the SEC. These forward-looking statements are made as
of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-announces-appointment-of-dr-gail-wilensky-to-its-board-of-directors-300885982.html
SOURCE ViewRay, Inc.